Withus Pharmaceutical Co

Withus Pharmaceutical Co FCF Yield

The Free Cash Flow Yield of Withus Pharmaceutical Co (330350.KQ) as of Nov 3, 2026 is 3.37 %. In the previous year, Free Cash Flow Yield was 2.82 % — a change of 19.54% (higher).

FCF Yield

3.37 %

YoY

19.54%

Last updated:

Free Cash Flow Yield of Withus Pharmaceutical Co is 2025 3.37 % . Free Cash Flow Yield of Withus Pharmaceutical Co was 2024 2.82 % . It decreases by 19.54% higher compared to the previous year.

The Withus Pharmaceutical Co FCF Yield history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Yield
Date
FCF Yield
Jan 1, 2018
4.42 KRW
Jan 1, 2019
2.99 KRW
Jan 1, 2020
-4.10 KRW
Jan 1, 2021
1.25 KRW
Jan 1, 2022
-9.15 KRW
Jan 1, 2023
-12.17 KRW
Jan 1, 2024
2.82 KRW
Jan 1, 2025
3.37 KRW
The Withus Pharmaceutical Co FCF Yield history
YEARFCF YieldYoY
3.37 %+19.54%
2.82 %-123.17%
-12.17 %+33.02%
-9.15 %-834.86%
1.25 %-130.40%
-4.10 %-236.80%
2.99 %-32.21%
4.42 %+13.01%
3.91 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Withus Pharmaceutical Co Stock analysis

What does Withus Pharmaceutical Co do? Withus Pharmaceutical Co Ltd is a pharmaceutical company based in Seoul, South Korea, operating within the healthcare sector. The company focuses on the manufacturing and distribution of prescription drugs, with its headquarters located in Seoul. As of the latest available information, Withus Pharmaceutical employs 191 full-time staff members. The company completed its initial public offering (IPO) on July 3, 2020, marking its entry into the public market. Its primary product categories include circulatory agents, musculoskeletal agents, digestive agents, antibiotics, and other prescription medications. Additionally, the company engages in contract manufacturing operations (CMO), providing manufacturing services for other pharmaceutical entities. Withus Pharmaceutical maintains a corporate website at https://www.withuspharm.com/mastart/mastart.php, which serves as a platform for company information and updates. The company operates in the pharmaceutical industry, contributing to the production and supply of essential medications in South Korea. Withus Pharmaceutical's business model integrates both direct product sales and contract manufacturing services, supporting its role in the broader healthcare ecosystem. The company's operations are centered around the development and delivery of prescription drugs, with a focus on key therapeutic areas such as cardiovascular health, musculoskeletal conditions, gastrointestinal treatments, and infectious disease management. The firm's activities are conducted under the regulatory framework of South Korea's pharmaceutical industry, adhering to local standards for drug manufacturing and distribution. Withus Pharmaceutical Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Withus Pharmaceutical Co stock

Free Cash Flow Yield of Withus Pharmaceutical Co is 3.37 % in 2025.

Free Cash Flow Yield of Withus Pharmaceutical Co changed from 2.82 % to 3.37 %, representing a 19.54% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Free Cash Flow Yield Withus Pharmaceutical Co since 2006 – with annual values, charts, and detailed analysis.

FCF Yield measures the free cash flow per share relative to the stock price. It indicates how much cash a company generates for each dollar invested.

To evaluate Free Cash Flow Yield's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Free Cash Flow Yield.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Free Cash Flow Yield's Withus Pharmaceutical Co with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Withus Pharmaceutical Co

All Key Metrics — Withus Pharmaceutical Co